COMPOSITION:

Each tablet contains sustained release Vildagliptin 100 mg.

DESCRIPTION:

Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults

MECHANISM OF ACTION:

The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion.

By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.

The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.

INDICATIONS:

Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults as monotherapy, as dual oral therapy in combination with metformin, sulphonylurea & thiazolidinedione, in combination with insulin, and as triple oral therapy in combination with sulphonylurea and metformin.

 

DOSAGE & ADMINISTRATION:

Recommended daily dose of vildagliptin sustained release tablet is 100 mg with or without food.

CONTRAINDICATIONS:

Vildagliptin is contraindicated in patients with known hypersensitivity to vildagliptin or to any of the excipients.

 

DISCLAIMER: All content published online is for informational purposes only. It is not intended to be a substitute for professional medical advice. Always seek the guidance of your doctor with any questions you may have regarding your health, medical condition, or any medicines.